

CLAIM AMENDMENTS

1-53. (canceled)

54. (new): A method of treating a subject being treated with a neoplastic agent in an amount sufficient to cause a side effect selected from the group consisting of myelosuppression, mucositis and peripheral neuropathy, which method comprises administering to said subject an amount of N-palmitoyl-S-[2(R,S),3-dilauroyloxy-propyl]-(R)-cysteine (JBT 3002) in an amount sufficient to alleviate or prevent said side effect.

55. (new): The method of claim 54, wherein said JBT 3002 is encapsulated in liposomes.

56. (new): The method of claim 55, wherein said liposomes are multilamellar liposomes.

57. (new): A method to ameliorate a side effect of anti-neoplasia treatment in a subject, wherein said side effect is myelosuppression, mucositis or peripheral neuropathy, which subject is undergoing treatment with an anti-neoplasia agent, which method comprises administering to said subject a pharmaceutical composition comprising JBT 3002.

58. (new): The method of claim 57, wherein said JBT 3002 is encapsulated in liposomes.

59. (new): The method of claim 58, wherein said liposomes are multilamellar liposomes.

60. (new): A method to ameliorate a side effect of anti-neoplasia treatment in a subject, wherein said side effect is myelosuppression, mucositis or peripheral neuropathy, which subject has been treated with an anti-neoplasia agent, which method comprises administering to said subject a pharmaceutical composition comprising JBT 3002.

61. (new): The method of claim 60, wherein said JBT 3002 is encapsulated in liposomes.

62. (new): The method of claim 61, wherein said liposomes are multilamellar liposomes.